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TIIVISTELMÄ 
Tutkimuksen tausta ja tavoitteet: Eturauhassyöpä on miesten yleisin syöpä länsimaissa. Se 
on erittäin heterogeeninen sairaus niin kliinisesti kuin geneettisestikin. Eturauhassyöpään 
liittyy lukuisia genomin uudelleen järjestäytymisiä, joista yleisimpiä ovat kromosomialueiden 
kopiolukumuutokset. Eräs hiljattain löydetty toistuva monistunut kromosomialue on 9p13.3. 
Tämän tutkimuksen tavoitteena oli tutkia voisiko UNC13B olla tämän uuden kromosomi-
monistuman kohdegeeni eturauhassyövässä. Tämä työ on osa laajempaa 9p-kromosomi-
alueen tutkimusta. 
 
Tutkimusmenetelmät: UNC13B:n ilmentyminen määritettiin lähetti-RNA-tasolla (mRNA) 
kvantitatiivisella käänteiskopiointipolymeraasiketjureaktiolla (RT-qPCR) eri eturauhassyöpä-
solulinjoista. PC-3-, MCF-7- ja LNCaP-solulinjat transfektoitiin väliaikaisesti UNC13B-
cDNA:lla, ja yli-ilmentyminen varmistettiin mRNA-tasolla RT-qPCR:lla sekä proteiinitasolla 
immunoblottauksen ja –sytokemian avulla. UNC13B:n toimintaa tutkittiin yli-ilmentämällä 
sitä PC-3- ja MCF-7-soluissa, ja analysoimalla yli-ilmentymisen vaikutusta solujen 
jakautumis- ja migraatiokykyyn. Näiden tutkimusten lisäksi UNC13B:n ilmentyminen 
määritettiin kliinisistä eturauhassyöpänäytteistä RT-qPCR:n ja immunohistokemian avulla. 
 
Tutkimustulokset: UNC13B-geenin ilmentymistasot vaihtelivat eri syöpäsolulinjojen välillä. 
UNC13B:n yli-ilmentyminen PC-3-soluissa lisäsi jonkin verran solujen jakautumista, mutta 
toisaalta yli-ilmentymistaso osoittautui matalaksi tässä solulinjassa. Yli-ilmentymisellä ei 
ollut vaikutusta PC-3-solujen migraatiokykyyn. UNC13B:n yli-ilmentymisen vaikutusta 
MCF-7-solujen jakautumiseen oli haastavaa tutkia, sillä solut tuottivat epätavallisen suuren 
määrän UNC13B-proteiinia transfektiolla aiheuttaen solukuolemaa. Tulokset kliinisten 
eturauhassyöpänäytteiden analyysistä viittaavat, että korkeammalla UNC13B-geenin 
ilmentymisellä saattaa olla rooli edistyneemmässä eturauhassyövässä vaikkakaan tulokset 
eivät ole tilastollisesti merkittäviä. Hormonirefraktorisissa (HR) näytteissä esiintyi korkein 
UNC13B:n  ilmentymisen keskiarvo verrattuna näytteisiin eturauhasen hyvänlaatuisesta 
liikakasvusta ja primaarisyövästä. Muutamassa HR-näytteessä havaittiin myös erityisen 
korkea UNC13B-ilmentyminen mRNA-tasolla. 
 
Johtopäätökset: Kliinisten eturauhassyöpänäytteiden analyysin tulokset viittaavat siihen, että 
korkeammat UNC13B-ilmentymistasot saattavat liittyä edistyneempiin syöpätapauksiin ja/tai 
syövän etenemiseen. UNC13B-geenin ilmentymisprofiilin voisi täten yhdistää muihin 
parametreihin eturauhassyövän aggressiivisuuden ennustamisessa. UNC13B:n toiminnallinen 
rooli syöpäsoluissa ei selvinnyt tässä tutkimuksessa. Lisää tutkimuksia tarvitaan selvittämään 
UNC13B:n potentiaalista roolia eturauhassyövän ennustettavuuden biomarkkerina. 
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ABSTRACT 
Backround and aims: Prostate cancer is the most common cancer in men in Western 
countries. It is a highly heterogeneous disease both clinically and genetically. Multiple 
genomic rearrangements are associated with the disease, copy number alterations being the 
most common ones. One recently found recurrently amplified chromosomal region is 9p13.3. 
The aim of this thesis was to study whether UNC13B is a potential target gene of this novel 
amplification in prostate cancer. This thesis is part of a broader study of 9p chromosomal 
region in prostate cancer. 
 
Methods: The expression of endogenous UNC13B mRNA was determined with RT-qPCR 
from different prostate cancer cell lines. PC-3, MCF-7 and LNCaP cancer cells were 
transiently transfected with UNC13B. Overexpression was verified by RT-qPCR analysis at 
mRNA level, and by immunoblotting and immunocytochemistry at protein level. The 
functional role of UNC13B was studied by overexpressing UNC13B in PC-3 and MCF-7 
cells, and assaying the effect on cell growth and migration ability. In addition, the expression 
of UNC13B was determined from clinical prostate cancer specimens by using RT-qPCR and 
immunohistochemistry. 
 
Results: The levels of UNC13B overexpression showed variability in studied cell lines. 
Overexpression of UNC13B slightly increased the proliferation of PC-3 cells; however the 
overexpression status proved to be low in PC-3 cells. Overexpression did not affect migration 
ability of PC-3 cells. The effect of UNC13B overexpression on MCF-7 cell growth was a 
challenge to determine since the cells exhibited abnormally large amounts of UNC13B 
protein upon transfection causing cell death. The results from clinical tumor sample analyses 
suggest that higher UNC13B expression might have a role in more advanced disease although 
the results were not statistically significant. Compared to benign prostatic hyperplasia and 
primary prostate cancer, the hormone refractory cancer samples showed the highest mean 
expression and also a few cases of particularly high UNC13B expression at mRNA level. 
 
Conclusion: The results from clinical samples analyses indicate that higher UNC13B 
expression levels might be associated with more advanced disease and/or disease progression. 
This suggests that UNC13B expression profile could potentially be combined with other 
parameters to predict the aggressiveness of the disease. The functional role of UNC13B in 
cancer cells remains a question. More studies are needed to assess the potential use of 
UNC13B as a prognostic biomarker. 
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1. INTRODUCTION 
Prostate cancer is the most common cancer in men, both in Finland and other Western 
countries. In 2007 – 2011 in Finland, nearly 4500 new cases were diagnosed annually and 824 
cancer related deaths were registered annually (www.cancer.fi/syoparekisteri/en/; 
16.12.2013). Like in other cancers, the incidence of prostate cancer is growing. This is largely 
caused by ageing of the population and improved screening and diagnostic methods. 
Increasing number of men is being diagnosed with very early stage prostate cancer due to the 
widespread use of prostate specific antigen (PSA) testing. 
 
The risk of prostate cancer is strongly age related. Approximately 40% of men over age of 50 
have slow-growing and well-differentiated prostate cancer; of these cancers, approximately 
10% become clinically significant and only 3% contribute to cause of death (Haas et al., 
2008). In general, most of the cases are diagnosed in the age range of 70 to 74. The survival 
ratio of prostate cancer is rather good because most men diagnosed at a very early stage will 
die with prostate cancer but not from it (Hughes C et al., 2005). The 5-year survival ratio in 
Finland registered in 2007 - 2011 was 97% (www.cancer.fi/syoparekisteri/en/; 16.12.2013). 
 
Prostate cancer is a highly heterogeneous disease in both clinically and genetically. Typical 
feature for prostate cancer is slowly growing tumors which cause no life-threatening condition 
for patients. Also the disease metastasizes rarely. However, some prostate tumors are highly 
aggressive, metastasize early and ultimately develop to castration resistant prostate cancer 
(CRPC) with only limited treatment options. One of the key questions in the prostate cancer 
research and in clinics nowadays is how to distinguish aggressive tumor types from the 
indolent ones at early stage. This could be achieved by identifying potential biomarker genes 
which are involved in prostate cancer progression. 
 
Prostate cancer is associated with multiple genetic alterations, including somatic point 
mutations and variable genomic rearrangements. Genetic heterogeneity of the disease can be 
seen between patients and within a patient; prostate cancer is often multifocal meaning as 
many as 5 to 6 tumors with different genetic profiles occurring in a single prostate. In general, 
somatic point mutations are relatively rare compared to other cancers while gene copy number 
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alterations are much more common (Taylor et al., 2010). Furthermore, gene fusions are 
relatively common, most frequent being TMRPSS2:ERG fusion (Pettersson et al., 2012). 
 
A novel recurrent amplification in the chromosomal region 9p13.3 has been detected in 
prostate cancer (Saramaki et al., 2006; Taylor et al., 2010). According to previous studies, 
10% and 33% of prostatectomy treated patients gain high-level and low-level amplifications, 
respectively (Leinonen, 2007). Of hormone-refractory tumors, 14% contain high-level 
amplification and and 44% low-level amplification (Leinonen, 2007). The novel amplicon 
contains multiple target genes whose expression correlates with increased copy number, 
however, no cancer associated genes have been identified so far (Leinonen, 2007). In this 
research, one of these potential candidate genes, UNC13B, was studied in more detail in order 
to see whether it could be the target gene of 9p13.3 amplicon and whether it could be used as 
a new prognostic marker for prostate cancer. 
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2. REVIEW OF LITERATURE 
2.1 Prostate cancer 
Prostate cancer arises from prostate gland located in the male pelvis between the bladder and 
the penis (Figure 1). The walnut-sized prostate gland belongs to the accessory sex gland 
system in males that synthesizes and secretes many components of the seminal plasma 
including male sex hormones. It is believed that the spermatozoa survival in the female 
reproductive tract is largely enhanced by prostatic secretions although fertilization isn´t 
dependent on prostatic fluids. 
 
 
Figure 1. The prostate gland. The prostate gland is located below the bladder, just in front 
of the rectum, and it surrounds the urethra. Picture is modified from http://prostate-health-
net.com/prostate_picture.html (20.02.2015). 
 
2.1.1 Anatomy of the prostate 
Prostate gland can be divided into four zones: peripheral zone, central zone, anterior fibro-
muscular zone, and preprostatic region (Young & Heath, 2000) (Figure 2). The zonal anatomy 
of the prostate was developed and reported by McNeal in 1981 (McNeal JE, 1981), and it 
allows the assignment of the zone of origin to individual prostate cancer foci. A fibroelastic 
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band, rather than a capsule, encloses the posterior and lateral surfaces of the prostate gland 
while fibro-muscular stroma surrounds the apical and anterior parts (Raychaudhuri B et al., 
2008). The anterior fibro-muscular stroma lacks entirely glandular elements. Instead, it 
consists of connective tissue and both smooth and skeletal muscle. Peripheral zone constitutes 
over 70% of the glandular prostate and almost all (68%) carcinomas arise here (McNeal JE, 
1981). The peripheral zone consists of pseudostratified secretory epithelium with columnar 
cells and basal cells which are supported by a fibroelastic stroma. When peripheral zone 
surrounds the distal urethra, the central zone (25% of the glandular prostate) surrounds the 
ejaculatory ducts. 
 
 
Figure 2. View of the prostate gland and urethra. Prostate gland is divided into three 
zones: the central zone (CZ), the transition zone (TZ) and the peripheral zone (PZ). The 
seminal vesicles and ejaculatory ducts are located at the base of the prostate. The anterior 
fibromuscular stroma (AFS) is located anteriorly. Picture is modified from Wein AJ, 
Campbell-Walsh Urology 9
th
 Edition, 2007. 
 
The central zone is a region rarely associated with carcinoma. However, there are suggestions 
that small percentage of tumors arising from this region tend to be more aggressive than 
peripheral zone cancers with a far greater risk of extracapsular extension and seminal vesicle 
invasion (Cohen RJ et al., 2008). The preprostatic region including the periurethal ducts and 
transition zone is the smallest of the four zones. The small ducts in the transition zone are the 
exclusive site of benign prostatic hyperplasia (BPH) and about 24% of prostate cancers arise 
from this region (McNeal JE, 1981). 
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Over 95% of prostate cancers are adenocarcinomas that arise from prostatic epithelial cells 
(Verhagen PC et al., 2002). Like in all carcinomas, the differentiated epithelial cells transform 
through activation of oncogenes and loss of tumor suppressor genes, which leads to a growth 
and survival advantage (Taichman RS et al., 2007). However, prostate carcinogenesis is not 
only a result of DNA damage that occur in epithelial cells, it is a result of complex interplay 
of genes, the cellular microenvironment, the macroenvironment of the host, and the 
environment where the host resides (Toivanen et al., 2012). Multiple genetic changes have 
been associated with prostate cancer, however the genetic changes which will eventually lead 
to tumorigenesis are not well understood. 
2.1.2 Tumorigenesis 
At first, prostatic intraepithelial neoplasia (PIN) lesions will form that are characterized by the 
proliferation of secretory cells and loss of distinct basal and secretory layers (Schulz WA et 
al., 2003). PINs are graded as low-grade (LGPIN) to high-grade (HGPIN) according to the 
severity of dysplasia of the epithelial cells, and especially HGPIN resembles prostate cancer 
(Montironi R et al., 2011). According to many studies of animal models and man, PIN is the 
only accepted precursor of prostatic adenocarcinoma (Bostwick DG et al., 2012; Montironi R 
et al., 2011). Similarities between PIN and cancer are nuclear and nucleolar enlargement, 
partial basal cell layer distruption indicating possible stromal invasion, multifocality and 
similar zonal distribution (Bostwick DG et al., 2012). In addition, PIN and prostate cancer 
have comparable genetic alterations (Bostwick DG et al., 2012) with a difference that cancer 
obtains more of these changes. 
2.1.3 Gleason grading system 
Prostate adenocarcinomas are typically graded by patterns of gland formation in order to 
determine the degree of differentiation. Grading systems are used in cancer diagnostics and 
prognostics to evaluate the differentiation and aggressiveness of the cancer. A widely 
accepted method for grading the histological differentiation of prostate cancer is Gleason 
grading system developed by Donald F Gleason in the late 60´s (Figure 3). This system is 
based on two levels of scoring because of the histological variation within each tumor 
(Harnden P et al., 2007). The most prominent histologic pattern and the second most common 
pattern are both assigned a grade of 1 to 5. These two grades are then summed and reported as 
the total Gleason score. A low Gleason score (<6) is considered as a more indolent 
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malignancy with a good prognosis whereas a high Gleason score (>8) is associated with an 
aggressive biological behavior and a potential risk of systemic disease. Gleason grading 
system is less successful in the prognosis of moderately differentiated cancers (Gleason score 
5-7). 
 
Figure 3. Schematic diagram of Gleason grading system. Numbers refer to Gleason 
grades. Above are the original Dr. Gleason´s drawing of each grade and below are the 
corresponding HE stained micrographs for each grade. Picture is modified from Harnden et 
al., 2007. 
2.1.4 Non-malignant prostate diseases 
There are different types of non-cancerous problems of the prostate including prostatitis and 
benign prostatic hyperplasia (BPH). Prostatitis is the most common prostate problem in men 
under the age of 50 and it is defined as inflammation of the prostate gland. In Finland, the 
overall lifetime prevalence of prostatitis is 14.2% (Mehik et al., 2000) while the overall 
prevalence rate is 5-9% (Jiang et al., 2013). Prostate inflammation can be caused by bacterial 
infection, such as common Escherichia coli, and the infection can be either acute or chronic. 
Prostatitis can also occur as inflammatory chronic pelvic pain syndrome in the absence of 
known infecting organism, or noninflammatory syndrome where both inflammation and 
infection-fighting cells are missing. Asymptomatic inflammatory prostatitis lacks common 
symptoms of prostatitis, such as urination difficulties, fever, lower back and/or pelvic pain, 
but inflammatory cells are still present. There are suggestions that the high prevalence of 
prostatitis could contribute to prostate carcinogenesis since the free radicals produced by 
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inflammation tissue increases the cancer risk by suppressing antitumor activity (Lonkar & 
Dedon, 2011). 
 
Benign prostatic hyperplasia (BPH) is also a common urological condition in men older than 
60 caused by the non-cancerous enlargement of the prostate (Russo et al., 2014). The 
oversized prostate can block urethra and cause multiple lower urinary tract symptoms such as 
difficulty in the beginning of urination and the need to frequently empty the bladder, 
especially during night time. BPH can be treated by active surveillance if the symptoms are 
mild or by medical therapies such as alpha blockers or 5α-reductase inhibitors if the patient is 
bothered by the symptoms (Wang et al., 2014). The aim of the drug treatment is to improve 
the quality of life of the patient by relieving the symptoms and slowing down the clinical 
progression of the disease (Wang et al., 2014). 
 
Although according to present knowledge, BPH is a non-malignant condition and not a 
precursor of prostate cancer, there seems to be some association between these two 
conditions. They are both among the most common diseases of the prostate gland and share 
some features such as hormone-dependent growth and response to antiandrogen therapy 
(Orsted & Bojesen, 2013). Also chronic inflammation and metabolic disruption are common 
risk factors for both diseases (Orsted & Bojesen, 2013). The important differences between 
BPH and prostate cancer include histological and localization aspects. BPH is most often 
localized in the transition zone of the prostate gland and histologically defined as the 
hyperplasia of the stromal cells, while prostate cancer is an adenocarcinoma arising primarily 
from epithelial cells in the peripheral zone of the gland (De Nunzio et al., 2011). According to 
large-scale epidemiological studies, men with BPH have an elevated risk of prostate cancer 
and prostate cancer-related mortality (Chokkalingam et al., 2003; De Nunzio et al., 2011). 
However, it is still unclear whether there is a causal link between BPH and prostate cancer or 
if they just develop under the same pathophysiological conditions. More epidemiological 
studies are needed to determine the pathways connecting BPH and prostate cancer. 
2.1.5 Risk factors 
After age-related risks, the second largest risk factor for prostate cancer is race, and the 
incidence of prostate cancer varies widely between ethnic populations and countries. Asian 
men typically have very low incidence of prostate cancer, with age-adjusted incidence rates 
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ranging from 2 to 10 cases per 100,000 men (Haas et al., 2008). Higher incidence rates are 
generally observed in northern European countries and in the United States. African 
American men, however, have the highest incidence of prostate cancer in the world. In the 
United States, black American men have a 60% higher incidence rate than Caucasian 
American men (Haas et al., 2008). The reason for this is not clearly understood; African 
American men may have a genetic predisposition to prostate cancer, and/or the incidence is 
dependent on environmental factors. 
 
Prostate cancer has a strong hereditary factor and a positive family history is the strongest risk 
factor after age and ethnic background. According to epidemiological studies, dominantly 
inherited susceptibility genes with high penetrance may cause 5 – 10% of all prostate cancer 
cases, and a vast majority of early onset diseases (Bratt, 2002). The lifetime risk for the 
development of prostate cancer increases 2-3 fold in men with one first-degree relative 
(father, brother) with prostate cancer (Chen YC et al., 2008). A characteristic for familial 
prostate cancer is that it tends to be diagnosed at a younger age than sporadic disease (Norrish 
AE et al., 1999). 
2.1.6 Treatment 
The treatment options for localized and organ-confined (localized only within the prostatic 
capsule) prostate cancer are active surveillance and radical prostatectomy. Active surveillance 
can be used because prostate cancer often grows slowly and some men might never need 
treatment for their prostate cancer. Organ-confined or locally spread cancer can be treated 
with surgery known as radical prostatectomy where the entire gland and also, if needed, some 
of the tissue around it are removed. Radiation therapy can be used as the first treatment for 
low-grade local cancer but also if the cancer has spread into nearby tissues. In advanced 
cancer, radiotherapy is used to reduce the size of the tumor and to relief the patient´s 
symptoms. The standard care for treating advanced metastatic prostate cancer is hormonal 
therapy. Androgen ablation therapy is used to stop the production of androgens which are 
important for prostate cancer to grow and develop. Unfortunately, many tumors develop 
resistance to hormone therapy and begin to grow and spread again after a while. Treatment 
options for hormone-resistant (or hormone refractory) prostate cancer are limited. (Prostate 
cancer: Current Care Guidelines Abstract, 2014.) 
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2.2 Prostate cancer genetics 
Genomic instability is a fundamental feature of human cancers and a critical factor for the 
creation of variants within a tumor cell population. The instability drives clonal evolution and 
heterogeneity seen within individual tumors and among tumors of the same type, progression 
to malignant disease, and therapy resistance (Cahill et al., 1999). Prostate cancer is a highly 
heterogeneous disease in both clinically and genetically. The disease can vary from indolent, 
low-risk cancer to lethal castration resistant metastatic disease. The main issue in the clinics 
today is to segregate treatable low-risk disease from aggressive type of tumors. Overdiagnosis 
and overtreatment are a problem in the case of low-risk cancer leading to an inappropriate 
morbidity. Hence it is important to identify prognostic and predictive signatures of prostate 
cancer based on genomic profiles. 
 
New screening techniques have revealed that prostate cancer is associated with multiple 
genomic rearrangements including somatic point mutations, small inversions and deletions, 
copy number alterations and gene fusions (Baca & Garraway, 2012; Tapia-Laliena et al., 
2014). In addition, intrachromosomal and interchromosomal rearrangements do occur as well 
as extensive genome-modifying events such as chromothripsis or chromoplexy (Tapia-
Laliena et al., 2014). Many potential target genes analyzed so far can be activated or 
deactivated by many different types of mutation. For example, variations in the androgen 
receptor gene expression can arise through somatic point mutations and focal amplification 
(Taylor et al., 2010). 
2.2.1 Biomarker study of prostate cancer 
Over the recent years, the amount of information about the molecular biology of cancer has 
increased tremendously. A great challenge is to translate this information into clinical 
applications. Despite the work done in the field of prostate cancer research, molecular 
mechanisms for the onset and progression of this disease still remain largely unknown. 
 
Molecular biomarker can be defined as “a substance found in tissue, blood, or other body 
fluids that may be a sign of cancer or certain benign conditions” (National Cancer Institute, 
14.2.2013). Tumor biomarkers can be specific cells, molecules, genes, gene products or 
hormones which can be detected from body fluids or tissues. Tumor markers are usually 
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present in both normal and cancerous conditions but the amount of marker to be detected is 
altered in malignant conditions. An optimal biomarker would be sensitive, specific and easily 
detected by noninvasive method e.g. from urine sample. 
 
Molecular biomarkers can serve as useful diagnostic markers, as prognostic markers for 
prediction of clinical outcome and response to therapy, or as targets for new therapies. In 
prostate cancer research, the major goals for identifying biomarkers are to better define 
groups of men at high risk of developing cancer, to improve screening techniques, to 
distinguish indolent and aggressive disease, and to improve therapeutic strategies in patients 
with advanced disease. 
 
A wide variety of putative biomarkers for prostate cancer diagnostic and prognostic have been 
discovered. However, due to the heterogeneous nature of the disease, there is no single 
biomarker described so far which would provide sufficient information of the disease 
independent of other information (Shariat et al., 2011). Therefore, a personalized approach 
could be a solution for prostate cancer dilemma. Knowledge of biomarkers could be 
combined with patient’s individual clinical data to create a model for evaluation of disease 
progression and therapy opportunities. 
 
There are many challenges in the research of novel biomarkers and to utilize them into 
clinical practice. First of all, the amount of data gained from numerous high-throughput 
studies has led to a massive increase of genomic information and identification of a myriad of 
candidate molecular biomarkers and therapeutic targets of prostate cancer. Each putative 
biomarker will require proper validation to ensure clinical utility and the validation should be 
performed on data not used to discover the biomarker (Sardana G et al., 2008). A 
standardization of analytical methodology, reference material, and quality control issues are 
essential to ensure the accuracy and reproducibility of the results (Bensalah et al., 2007). It 
has been suggested that the development of new biomarkers should follow similar principles 
than therapeutic drug evaluation including highly regulated phases (Shariat et al., 2011). It 
should be recognized that biomarker development might not be any easier than drug 
development and that the success rate of entering new biomarkers into clinical use is poor. 
 
The only current and clinically approved biomarker for prostate cancer is prostate specific 
antigen (PSA). PSA is a serine protease produced by both normal and neoplastic epithelial 
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cells of the prostate and it belongs to the human kallikrein gene family. The introduction of 
PSA testing into clinical practice in the late 1980s and early 1990s has led to a doubling of 
incidence of prostate cancer and a reduction in mortality in most Western countries (Bratt & 
Lilja, 2015). However, at the same time, overdiagnosis and overtreatment has grown 
tremendously because elevated serum PSA can exist without detection of prostate cancer 
(Romero Otero et al., 2014). Increased serum PSA may also reflect the presence of BPH, 
infection or chronic inflammation. The most problematic are intermediate PSA levels which 
show poor correlation with grade and progression of prostate cancer (Bratt & Lilja, 2015). 
2.2.2 Potential target genes in prostate cancer 
Genes that are recurrently altered in prostate cancer include several important tumor 
suppressor genes and oncogenes such as TP53, RB1, PTEN, MYC, PIK3CA, SPOP, and AR. 
These genes can be affected by many different mechanisms of mutation that affect the overall 
expression and function of the gene product. 
 
The androgen receptor (AR) regulates cellular proliferation and differentiation in the prostate 
epithelium in response to hormone signals. AR is a member of steroid hormone receptor 
transcription factor superfamily and it functions as a transcription activator of many target 
genes and gene networks. Human AR gene is located in chromosome X. The AR gene is 
frequently mutated in metastatic and castration-resistant disease (Linja & Visakorpi, 2004). 
However, AR is rarely mutated in primary tumors (Baca & Garraway, 2012). The AR gene 
expression can be altered by different mechanisms. Taylor et al. showed that AR gene was 
genetically altered by both somatic point mutations and focal amplification, and these 
aberrations were exclusively found in the metastatic tumor samples (Taylor et al., 2010). 
Furthermore, the AR collaborating factor FOXA1 was found to be mutated in both localized 
and hormone-resistant prostate cancer (Grasso et al., 2012). The mutated FOXA1 represses 
androgen signaling and increases tumor growth (Grasso et al., 2012). 
 
TP53 (coding p53 protein) is frequently mutated in human cancers. p53 acts as a transcription 
factor in response to cellular stress such as DNA damage, and regulate different transcription 
pathways that ultimately lead to tumor suppression. Usually the mutation of TP53 is loss-of-
function mutation but also mutant p53 that acquire oncogenic functions have been observed in 
some cancers (Muller & Vousden, 2013). TP53 mutations are more frequent in advanced 
12 
 
stages of prostate cancers than in early carcinoma which reflects that the mutation might be 
associated in the progression of prostate tumors (Isaacs & Kainu, 2001). However, even if 
TP53 is one of the most commonly mutated protein-encoding genes in prostate cancer, it is 
still relatively rare and associated with high heterogeneity within different tumors of the same 
prostate gland (Isaacs & Kainu, 2001; Taylor et al., 2010). 
 
Another commonly altered gene in prostate cancer is PTEN which encodes a lipid-protein 
phosphatase (Li et al., 1997). PTEN, located in 10q23, act as a part of the PI3K-PTEN-AKT 
signaling pathway which is aberrantly activated in prostate cancer (Baca & Garraway, 2012). 
Up to 70% of primary prostate cancers acquire loss of heterozygosity at the PTEN locus and 
5-10% contains inactivating mutations (Cairns et al., 1997; Gray et al., 1998). Aberrantly 
activated AKT pathway due to the functional loss of PTEN is one the most frequent 
abnormalities in prostate cancer progression (de Muga et al., 2010). Somatic PTEN deletions 
and mutations have been described in advanced adenocarcinoma with the frequency of 20 to 
60%, and the inactivation of the gene correlates with decreased cancer-specific survival (Baca 
& Garraway, 2012; de Muga et al., 2010). 
 
MYC is a known oncogene in various cancers, and its role in prostate cancer has been also 
widely studied (Tapia-Laliena et al., 2014). MYC is a transcription factor with a wide range 
of functions in cellular growth control, differentiation and apoptosis (Hoffman & Liebermann, 
2008). It is located in the chromosomal region 8q24 which is frequently amplified in prostate 
cancer; however, it is unclear whether MYC really is the candidate gene of this recurrent 
amplification (Fromont et al., 2013). The oncogene has been shown to be overexpressed at 
both mRNA and protein levels in prostate cancer (Fromont et al., 2013). 
  
The retinoblastoma (RB1) tumor suppressor gene is functionally inactivated in many human 
cancers and it acts as a central regulator of cell cycle progression (Burkhart & Sage, 2008). 
RB1 maintains control of the G1 to S-phase transition of the cell cycle primarily through 
interactions with the E2F family of transcription factors (Burkhart & Sage, 2008; Maddison et 
al., 2004). Loss of heterozygosity of the RB locus have been reported in 17 to 60% of prostate 
cancers and according to several studies the mutations of RB1 can be early events in prostate 
cancer (Maddison et al., 2004). Interestingly, a recent study showing that RB1 loss is a late 
event in prostate cancer suggests that RB deficiency may be specifically associated with the 
transition to castration resistant prostate cancer (Sharma et al., 2010). Also Taylor et al. 
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reported that loss of RB1 is more frequent in advanced prostate cancer than in primary tumors 
(Taylor et al., 2010). 
 
SPOP is a newly identified target gene in prostate cancer (Barbieri et al., 2012; Berger et al., 
2011). The gene encodes a SPOP subunit which is a substrate-recognition subunit of a class of 
cullin E3-ubiquitin ligases. Interestingly, the tumors harboring SPOP mutations lack a 
common chromosomal rearrangement found in prostate cancer, the TMPRSS2:ERG gene 
fusion (discussed below) (Barbieri et al., 2012). The discovery of SPOP mutated ERG 
rearrangement-negative prostate cancer might define a whole new subset of prostate cancer 
and help to stratify the patients in the future. 
2.2.3  Mutation rate and point mutations in prostate cancer 
A typical feature of prostate cancer genome profile is low somatic point mutation rate. The 
protein-altering mutation rate in prostate cancer was found to be ~0.3 per Mb (Taylor et al., 
2010), while in comparison in lung carcinoma the rate was 3.5 per Mb (Kan et al., 2010), and 
in malignant melanoma the frequency was found to be 30 per Mb (Berger et al., 2012). 
Surprisingly, there is only a moderate increase in the frequency of somatic point mutations 
when comparing localized and advanced prostate cancers (Grasso et al., 2012). Very few 
cases, however, exhibit a “hypermutated” phenotype with gross excess of point mutations 
which might result from alterations in DNA polymerase or DNA repair genes resulting in the 
accelerated rate of mutations (Kumar et al., 2011). 
 
The genes that are recurrently altered by somatic mutations include many important tumor 
suppressor genes and oncogenes mentioned above, such as TP53, RB1, PTEN, MYC, and 
SPOP (Grasso et al., 2012; Taylor et al., 2010). Alteration of AR expression through somatic 
mutation is also common in prostate cancer, especially in metastatic diseases (Taylor et al., 
2010). Also multiple chromatin/histone modifying genes, such as MLL2, have been identified 
to obtain recurrent point mutations (Grasso et al., 2012). In general, most prostate carcinomas 
are characterized by a lack of somatic driver mutations (Tapia-Laliena et al., 2014). Driver 
mutations are mutations that give selective advantage to cancer cell´s survival or growth in 
the microenvironment of the tissue in which the cancer arises. A driver mutation must have 
been selected at some point along cancer development but it may not be required for the 
maintenance of the final cancer. A major obstacle in cancer research is to distinguish genes 
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that carry driver mutations from those genes that obtain passenger mutations. Passenger 
mutations are biologically inert somatic mutations which have not been selected, have not 
conferred clonal growth advantage, and have therefore not contributed to cancer development. 
These mutations with no functional consequence will be carried in cancer genomes during 
cell divisions and will be present in all cells of the final cancer. 
2.2.4 Copy number alterations 
Copy number alterations are much more common in prostate cancer than somatic point 
mutations (Baca & Garraway, 2012). Multiple copy number gains and losses have been found 
to be associated with both localized and more advanced tumors. Comprehensive analyses 
have shown that these chromosomal alterations can stratify patients according to their risk for 
a disease recurrence and early cancer-specific mortality (Liu et al., 2013). Also, Taylor et al. 
showed that patients with tumors harboring no or few copy number alterations had more 
favorable prognosis than patients with tumors harboring excessive number of copy number 
alterations (Taylor et al., 2010). The challenge is to screen these altered regions and to find 
putative biomarkers that could be utilized in diagnosis and prognosis of the disease and that 
could be targeted for therapy. 
 
The extent of copy number alterations in prostate cancer tumors increases with the disease 
progression, and in general, losses are more common than gains. Pre-cancerous PIN lesions 
contain only modest number of alterations but the frequency increases while the disease 
progresses from localized adenocarcinoma to metastatic disease (Zitzelsberger et al., 2001). 
Frequent chromosomal losses have been identified in at least chromosomes 2q, 5q, 6q, 8p, 
10q, 13q, 16q, 18q, and 21q (Cheng et al., 2012). Recurrent gains have been identified in the 
chromosomes 3q, 7q, 8q, 9p, 17q, and Xq (Cheng et al., 2012). Few recurrent copy number 
alterations are concentrated in advanced tumors. For example, patients with hormone resistant 
prostate cancer show frequent amplification of chromosomes 7, 8q and X (Holcomb et al., 
2009). Potential target genes in these regions are AR (X) and MYC (8q) (Visakorpi et al., 
1995). 
 
The most frequent copy number alterations in prostate cancer are deletions of chromosome 8p 
(~30-50% of cases) and gains of 8q (~20-40%) (El Gammal et al., 2010; Taylor et al., 2010). 
Both alterations are relatively rare in early stages of prostate cancer and the frequency of 8p 
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loss doesn’t significantly increase from early to metastatic tumors (El Gammal et al., 2010). 
In contrast, the frequency of 8q gain increases steeply between early and advanced tumors 
indicating that the genes of this chromosome arm are relevant for the disease progression to 
deadly stages (El Gammal et al., 2010). The most interesting and intensively studied 
amplified loci on 8q region contains MYC gene (8q24.21) which is a frequently activated 
oncogene in many human cancers (Tapia-Laliena et al., 2014). Another interesting amplified 
gene at the 8q chromosome is the nuclear receptor coactivator gene NCOA2 (8q13.3) which 
has a known role as an AR coactivator (Taylor et al., 2010). 
 
Copy number alterations seem to have significant prognostic value in prostate cancer. For 
example, copy number alterations of PTEN and MYC were associated with an elevated risk 
for early cancer-specific mortality in a cohort of 333 men (Liu et al., 2013). Also, loss of 
PTEN together with ERG rearrangement status can predict an unfavorable prognosis of 
prostate cancer patients (Reid et al., 2010). These studies and many others have shown that 
combining different copy number alterations suitable for large-scale clinical application is a 
promising approach for patient risk stratification and selection of treatment choices. 
2.2.4.1 A novel 9p13.3 amplicon 
New small amplicon 9p13.3 (1.7 MB) was detected in prostate cancer cell lines (Kamradt et 
al., 2007; Taylor et al., 2010), xenografts (Leinonen, 2007, Saramaki et al., 2006; Taylor et 
al., 2010) and in clinical prostate tumors (Leinonen, 2007). Even 10% and 23% of 
prostatectomy treated patients harbor high-level and low-level 9p13.3 amplifications, 
respectively (Leinonen, 2007). Of hormone-refractory tumors, 14% contained high-level 
amplification, and 44% low-level amplification (Leinonen, 2007). The amplicon is located in 
the pericentromeric region of chromosome 9 and it is found by aCGH but not by cCGH due to 
its location near centromere (Kamradt et al., 2007; Saramaki et al., 2006). 
 
The region 9p13.3 contains over 40 known or predicted protein coding genes and some of 
these genes have been studied so far to find the putative target gene or genes for this 
amplicon. Kamradt et al. performed a genome-wide screening for chromosomal gains and 
losses on nine prostate cancer cell lines using aCGH, and the 9p13.3 amplicon was detected in 
CWR22 and CWR22-Rv1 cell lines (Kamradt et al., 2007). To further analyze the region, 
they quantified the copy number of the interleukin 11 receptor alpha gene (IL-11RA) and the 
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dynactin 3 gene (DCTN3), and showed that the copy number gain for IL-11RA is higher in 
both cell lines and primary prostate tumors. 
 
Saramäki et al. detected the novel amplicon in their study of genetic and expression 
alterations in prostate cancer (Saramaki et al., 2006). They used aCGH and found that the 
frequency of 9p13.3 amplification was 39% of studied prostate cancer cell lines and 
xenografts. When confirming the data by FISH, they found 3 genes in the amplicon region 
which showed significant association between increased copy number and expression. These 
genes were ubiquitin-conjugating enzyme E2R2 (UBE2R2), member of the CDC34 family; 
Dynactin 3 (DCTN3) which encodes for subunit of dynactin, a macromolecular complex 
binding to both microtubules and cytoplasmic dynein; and WDR40A, function of which is 
unknown. 
 
The 9p13.3 region was screened more precisely by Katri Leinonen in her Master´s thesis 
(Leinonen, 2007). The minimal region for the amplification, nearly 3.5 Mb, was determined 
by FISH. In order to find a putative target gene or genes for the amplicon, the mRNA 
expression levels and chromosomal copy number alterations for the genes in the region were 
screened by RT-qPCR and FISH, respectively, in 7 prostate cancer cell lines and 19 prostate 
cancer xenografts. The list of amplification target candidate genes was narrowed down by 
these methods and eight protein-coding genes passed the screening, (C9orf25, GALT, PIGO, 
UBAP1, UBAP2, UBE2R2, UNC13B and VCP) having the most promising correlation 
between gene expression levels and copy number status (unpublished results). 
 
These genes were further studied by siRNA-mediated downregulation in cell lines with either 
a normal copy number status or a gain in 9p13.3 (prostate cancer cell lines PC-3 and 22Rv1; 
breast cancer cell lines MCF-7 and BT-474). The proliferation rate of the cells decreased 
significantly by downregulation of several of these genes (GALT, PIGO, UBAP1, UBAP2, 
VCP) and also invasion of PC-3 cells was altered by downregulation of GALT and PIGO 
(unpublished results). 
2.2.5  Gene fusion 
The most common genomic abnormality in prostate cancer is gene fusion TMPRSS2:ERG. 
Approximately 40 to 50% of prostate cancers harbor the fusion (Pettersson et al., 2012). The 
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gene fusion involves two genes located in chromosome 21; TMPRSS2 (transmembrane 
protease, serine 2) and ERG (v-ets erythroblastosis virus E26 oncogene homolog). The 
oncogene ERG is a member of the erythroblast transformation specific (ETS) family of 
transcription factors which are involved in the regulation of proliferation, differentiation, 
apoptosis and other cellular processes (Clark & Cooper, 2009). The TMPRSS2 gene is 
androgen regulated and the fusion with ERG leads to the formation of an androgen-responsive 
oncogene (Pettersson et al., 2012). 
 
The mechanisms of the ERG fusion are only beginning to emerge but most likely involve 
transcription-associated DNA double-strand breaks (DBSs) (Haffner et al., 2010). It was 
found that androgen signaling leads to co-recruitment of AR and TOP2B (topoisomerase 2B), 
and TOP2B mediated DBS may be involved in the generation of TMPRSS2:ERG 
rearrangement in prostate cancer (Haffner et al., 2010). This finding is supported by another 
study where young men suffering from prostate cancer where found to not only have higher 
AR levels but also harbored ERG rearrangements more frequently than elderly patients 
(Weischenfeldt et al., 2013). 
 
Despite the potential significance of TMPRSS2:ERG fusion, the results gained from multiple 
studies are controversial. A positive association between TMPRSS2:ERG and prostate cancer 
progression have been found in some studies (Attard et al., 2008; Wang et al., 2006) while 
others have observed null, or inverse, association (Leinonen et al., 2010; Rostad et al., 2009). 
It seems that the presence of TMPRSS2:ERG fusion itself does not correlate with progression-
free or overall survival (Pettersson et al., 2012). However, when other parameters such as 
PTEN loss are combined with ERG rearrangements, the prognostic effect becomes significant 
(Reid et al., 2010). The presence of ERG rearrangement can be further used to subclassify 
prostate cancer when other cofactors are included in the analysis. For example, the mutation 
of SPOP gene occur only in TMPRSS2:ERG fusion-negative tumors (Barbieri et al., 2012). 
Furthermore, 43% of the tumors with ERG rearrangement also have TP53 mutations and 57% 
have simultaneous PTEN loss (Barbieri et al., 2012). 
2.2.6  Chromothripsis and chromoplexy 
In addition to point mutations, simple translocations and focal copy number changes, complex 
genome rearrangements are frequently observed in cancer. In recent years, these types of 
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massive chromosome-damaging events have been identified also in prostate cancer (Baca et 
al., 2013; Berger et al., 2011). Chromothripsis is defined as an event in which structural 
rearrangements occur in a clustered fashion after a catastrophic chromosomal breakage 
(Forment et al., 2012) (Figure 4). It can involve a single chromosome or a single arm of 
chromosome with tens to hundreds of rearrangements. Chromothripsis has an incidence of 2-
3% in a wide range of different cancers analyzed so far (Stephens et al., 2011). In contrast to 
chromothripsis, chromoplexy is an event involving chromosomal DNA located on multiple 
chromosomes (Figure 4). A massive DNA breakage event is followed by generation of 
chained patterns of chromosomal rearrangements and deletion bridges from up to 6 
chromosomes identified so far (Baca et al., 2013). Despite the extensive DNA damage 
associated with both events, there is evidence suggesting that instead of accumulating 
sequentially over time they occur as single events (Baca et al., 2013; Stephens et al., 2011). 
This challenges the classical view of cancer development where mutations and genomic 
alterations accumulate gradually over time in pre-cancerous cells. 
 
 
Figure 4. (A) Chromothripsis. A catastrophic chromosomal breakage can yield 10s to 100s 
of DNA fragments which are attempted to repair. Some fragments may be lost during the 
repair. Chromothripsis can generate several genomic lesions with potential to drive cancer in 
single event. (B) Chromoplexy. Three scenarios by which multiple DNA double-strand 
breaks (DSBs) may be repaired. Concerted repair with minimal loss of DNA (left) results in 
fusion breakpoints that map to adjacent positions in the reference genomes. Loss of DNA at 
sites of DSBs may result in simple deletions (middle) or “deletion bridges” (right) that span 
breakpoints from distinct fusions on the reference genome. Adjacent breakpoints or deletion 
bridges may provide evidence for chromoplexy. Pictures are modified from (A) Stephens et 
al., 2011 and (B) Baca et al., 2013. 
 
19 
 
As a consequence of chromothripsis and chromoplexy, the chromosomal regions are 
rearranged in a way that may promote carcinogenesis. This can occur if rearrangement has 
disrupted tumor suppressor genes and altered oncogene expression. Interestingly in prostate 
cancer, chromoplexy is more frequently observed in tumors containing oncogenic ERG fusion 
(Baca et al., 2013). ERG-overexpressing cancer cells accumulate DNA damage (Brenner et 
al., 2011) thereby potentially promoting chromoplexy if multiple breaks occur in spatially 
neighboring chromosomes. 
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3. AIMS OF THE RESEARCH 
 
UNC13B could be a potential target gene for 9p13.3 amplicon and it might function as a 
biomarker for prostate cancer. This study is part of a broader study of 9p chromosomal region 
in prostate cancer. In this study the aims are to examine the function of UNC13B in prostate 
cancer and breast cancer cell lines by UNC13B overexpression. UNC13B protein levels will 
be analyzed from cancer cell lines by immunoblotting and immunofluorescence, and the 
functional experiments include cell growth analysis, and migration analysis. Furthermore, the 
expression levels of UNC13B are analyzed from clinical prostate cancer specimens by RT-
qPCR and from clinical prostatectomy and hormone refractory prostate cancer tissue samples 
by immunohistochemistry. 
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4. MATERIALS AND METHODS 
4.1 Cell culture 
Human prostate cancer cell lines PC-3, LNCaP, DU145, 22Rv1, and human breast cancer cell 
line MCF-7 were obtained from American Type Culture Collection (ATCC, USA) whereas 
prostate cancer cell line LAPC4 was kindly provided by Dr. Charles Sawyers (Jonsson Cancer 
Center, UCLA, Los Angeles, USA), and prostate cancer cell lines VCaP and DuCaP were 
kindly provided by Dr. Jack Schalken (Radbound University Nijmegen Medical Centre, 
Nijmegen, The Netherlands). The cell lines were cultured under recommended conditions. 
The basal media used were DMEM (MCF-7), Ham’s F-12 (PC-3) and RPMI 1640 (LNCaP), 
all purchased from Sigma-Aldrich. Basal media were supplemented with 10% fetal bovine 
serum (FBS) and 2 mM L-glutamine, and the cells were cultured at 37ºC and 5% CO2. 
4.2 UNC13B transfection 
For functional assays, cells were transiently transfected with UNC13B cDNA cloned in 
pCMV6-XL4 expression vector (OriGene Technologies, Inc.). Transfection was performed 
using jetPEI® transfection reagent (Polyplus Transfection) according to manufacturer´s 
instruction using 500 ng of DNA per 1 cm
2 
area. Briefly, the UNC13B cDNA was diluted and 
incubated in Gibco® Opti-MEM® medium (Invitrogen). The jetPEI reagent was also diluted 
and incubated in Opti-MEM® medium following an addition of jetPEI solution to DNA 
solution. The transfection solution was incubated for 12 minutes before addition to cells. 
pSG5 vector was used as a control. 
4.3 Clinical prostate tumor specimens 
Previously extracted and reversely transcribed total RNAs from clinical benign prostatic 
hyperplasia, prostate cancer and hormone-refractory prostate cancer tissues were used in order 
to define the expression levels of UNC13B by RT-qPCR. Formalin-fixed and paraffin-
embedded samples of locally recurrent hormone-refractory prostate cancers and 
prostatectomy prostate tumors were obtained from Tampere University Hospital. Tissue 
microarrays (TMAs) were previously created from the cancer samples. The materials were 
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used in the consent of the patients and with the approvals of the ethical committee of the 
Tampere University Hospital and the National Authority for Medicolegal Affairs (TEO). 
4.4 RNA isolation and RT-qPCR 
UNC13B expression levels were analyzed with quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) from different prostate cancer cell lines, UNC13B transfected cell 
lines, and from clinical prostate tumor specimens. 
 
Total RNA was extracted from cells with TRI Reagent® (Molecular Research Center, Inc.) 
following the manufacturer´s protocol. Briefly, the cells were cultured in 6-well plate for 
RNA extraction. Cell densities for PC-3, LNCaP and MCF-7 cells were 200,000, 250,000 and 
300,000, respectively. UNC13B transfection was performed one day after the seeding and 
cells were lysed directly in the wells by TRI reagent on the next day after transfection. Next, 
phase separation was performed by adding chloroform and by centrifuging at 12,000 g for 15 
minutes at +4ºC. The separated aqueous phase was transferred into a fresh tube. RNA was 
precipitated from the aqueous phase by mixing with isopropanol and by centrifuging at 
12,000 g for 8 minutes at +4ºC. The precipitated RNA pellet was washed with 75% ethanol 
and subsequent centrifugation at 7,500 g for 5 minutes +4ºC. Washed and air-dried RNA 
pellet was solubilized in nuclease-free water and stored in -70ºC. 
 
The reverse transcription of RNA to cDNA was performed with AMV Reverse Transcriptase 
(Thermo Scientific). 1 µg of RNA was mixed with Fermentas Random Hexamer Primers 
(0.05 µg/µl; Thermo Scientific), and with sterile water. Primers were denaturated at 65ºC for 
10 minutes after which the mixture was chilled on ice. A mixture was prepared from rest of 
the reaction components: 10 mM dNTP mix (200 µM each), 10x AMV reaction buffer 
(Thermo Scientific), RNase inhibitor and AMV Reverse Transcriptase (Thermo Scientific). 
The reverse transcription reaction was performed for 60 minutes at 42ºC following 
subsequent enzyme inactivation at 70ºC for 15 minutes. The reactions were stored at -70ºC. 
 
Prior to RT-qPCR, the UNC13B primers and PCR reaction conditions were optimized by 
gradient PCR. Briefly, 1 µg of DNA was mixed with 10x Optimized DyNAzyme Buffer 
(Thermo Scientific), 10 mM dNTP mixture (200 µM each), DyNAzyme DNA polymerase 
(0.04 U/µl, Thermo Scientific), UNC13B primers (Proligo) and sterile H2O. Primers used to 
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detect UNC13B were 5´-ACGCTATGCCCTGTCTCTGT-3´ and 5´-TCTGCCACTTGA 
GGTCATTG-3´ (Proligo). The gradient PCR reaction conditions are listed in Table 1. 
 
Table 1. Gradient PCR conditions for UNC13B primer optimization. 
Program  Temperature (ºC) Time 
    
Initial denaturation 
40 cycles: 
 94 3 min 
Denaturation 
Annealing 
Elongation 
94 30 sec 
gradient 50 to 60 30 sec 
72 20 sec 
Final elongation  72 5 min 
 
 
Bio-Rad CFX96 Real-Time PCR equipment (Bio-Rad) was used to perform the quantitative 
RT-PCR. In every reaction, there were 2 µl of template, 0.125 µl of each UNC13B primer, 10 
µl of Fermentas Maxima™ SYBR Green/ROX qPCR 2x Master Mix (Thermo Scientific), 
and 8 µl of sterile H2O. The RT-qPCR reaction conditions used are listed in Table 2. 
 
Table 2. The quantitative RT-PCR reaction conditions. 
Program  Temperature (ºC) Time 
Denaturation 
50 cycles: 
 95 10 min 
Denaturation 
Annealing 
Elongation 
95 15 sec 
58 30 sec 
72 30 sec 
Melting:    
Denaturation 50 30 sec 
Annealing 65 -
 1 
Elongation To 95
1 
0.5ºC/5 sec
1 
1
Temperature was increased from annealing temperature to 95ºC at the rate of 0.5ºC/5 sec. 
 
The standard curve was prepared from previously extracted total RNA from LNCaP, 22RV1, 
and PC-3 cell lines. The RNAs were reversely transcribed and resulting cDNAs were pooled. 
The standard curve was prepared using 10-fold dilution series. Sterile water was used as a 
negative control. Expression values were normalized to housekeeping gene TBP (TATA 
binding protein). The results from RT-qPCR were confirmed by running the samples in 1% 
agarose gel electrophoresis. PCR results were analyzed using CFX Manager Sofware. 
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4.5 Protein work 
4.5.1 Protein isolation 
The cells were cultured in 6-well plate for protein collection. Cell densities for PC-3, LNCaP 
and MCF-7 cells were 200,000, 250,000 and 300,000, respectively. UNC13B transfection was 
performed as mentioned above. UNC13B transfection was performed one day after the 
seeding and cells were collected on the next day after transfection. The cells were washed 
three times with ice cold phosphate buffered saline (PBS) and collected with a cell scraper in 
1.5 ml of cold PBS. The tubes were centrifuged 200 g 3 min at +4ºC and extra PBS was 
pipetted off. Cell pellets were stored in -70ºC. 
 
The total protein was extracted using Triton lysis buffer supplemented with 25x complete 
protease inhibitor cocktail (Roche), 100 mM dithiothreitol (DTT, Invitrogen), and 100 mM 
phenylmethylsulfonyl fluoride (PMSF). Pelleted cells were suspended to lysis buffer, 
incubated on ice for 15 minutes and sonicated with Bioruptor™ (Diagenode Inc.). The 
samples were centrifuged for 10 minutes at 16 000 g at +4°C and the cleared supernatant 
containing the proteins was collected into a new tube. The lysates were stored in -70ºC. 
 
The protein concentrations of the lysates were measured using colorimetric Bio-Rad DC 
Protein Assay (Bio-Rad Laboratories) according to manufacturer´s protocol. The standard 
curve was prepared from 10 µg/ml bovine serum albumin (BSA) using 2-fold dilution series. 
The absorbances of the reactions were measured at 690 nm. 
4.5.2 SDS-PAGE 
Proteins were separated with sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The gel consisted a 5% resolving gel and a 3% stacking gel (Table 3). Triton 
lysis buffer was added to the volume of the sample including 25 to 40 µg protein to reach the 
total volume of 30 µl. Protein samples were boiled with SDS sample buffer/DTT (3x SDS 
sample buffer (New England BioLabs Inc.) and 1.25M DTT) at 95˚C for 5 minutes and 
sample was loaded into the gel. The samples were run first at 50V for 30min to concentrate 
the proteins and then at 150V for 1h 30min to separate the proteins. 
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Table 3. The reagents of SDS-PAGE gels. 
Reagent 5% resolving gel 3% stacking gel 
dH2O 
1.5M Tris pH8.8 
0.5M Tris pH6.8 
10% SDS 
30% Acrylamide/Bis-acrylamide 
5 ml 
2.25 ml 
- 
180 µl 
1.5 ml 
2.1 ml 
- 
865 µl 
34 µl 
340 µl 
Temed (N,N,N,N'-tetramethylenediamine) 
10% APS (ammonium persulfate) 
10 µl 6.6 µl 
40 µl 34 µl 
 
4.5.3 Western blot 
Western blot was used to evaluate the UNC13B protein amount from UNC13B transfected 
cell lines. The Immobilon-P PVDF membrane (Millipore, pore size 0.45 µm) was activated by 
soaking it in 100% methanol and then in transfer buffer (25 mM Tris, 190 mM glycine, 20% 
methanol, pH 8.3). Western blotting was performed with Trans-Blot SD Semi-Dry Transfer 
Cell (Bio-Rad). Blotting was performed at 50-100 Am for 1 to 1.5 hours depending on the 
size of the gel. 
 
The blotted PVDF membrane was blocked with 3% BSA overnight at +4ºC. Primary antibody 
against UNC13B (Sigma-Aldrich) was diluted 1:600 in 0.1% Tween 20/PBS, 3% BSA and 
0.1% NaN3. The antibody was incubated at room temperature on the membrane for 1 hour 
following three 10 minute washes with 0.1% Tween 20/PBS. The secondary antibody, 
horseradish peroxidase (HRP) conjugated swine anti-rabbit (Dako Cytomation) was diluted 
1:2000 in 0.1% Tween 20/PBS and 3% BSA, and incubated at room temperature for 1 hour. 
Washing was performed as previously mentioned. The detection of UNC13B was performed 
with chemiluminescence reagent (Western Blotting Luminol Reagent; Santa Cruz 
Biotechnology Inc) according to manufacturer’s protocol. The Super RX x-ray films 
(Fujifilm) were exposured for 10 minutes and processed using Agfa CP1000 Film Processor 
(Agfa Inc.). 
4.6 Fluorescence immunocytochemistry 
The cells were seeded in 6-well plate containing sterile cover slides in corresponding 
densities: PC-3 200,000 cells, MCF-7 300,000 cells, and LNCaP 250,000 cells per well. On 
the next day, the cells were transfected with UNC13B or pSG5 as mentioned previously. 24 
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hours after transfection the cover slides were rinsed with 1xPBS and the cells were fixed with 
4% paraformaldehyde (PFA) for 30 minutes following rinse with PBS. Permeabilization was 
performed with 0.5% NP-40 substitute (nonyl phenoxypolyethoxylethanol) (Sigma-Aldrich) 
for 5 minutes following wash with PBS, and blocking with 3% BSA/PBS for 10 minutes. 
Primary antibody against UNC13B (Sigma-Aldrich) was diluted 1:300 (1 µg/ml) in 3% 
BSA/PBS and the cover slides were incubated with the antibody in moisture chamber over 
night at +4°C. After the incubation the slides were washed three times 10 minutes with PBS, 
and incubated with secondary antibody Alexa Fluor® 594 goat anti-rabbit IgG (Invitrogen) 
(1:200 dilution in 3% BSA/PBS) for 1 hour at +37°C. Washes with PBS were repeated and 
the cover slides were mounted on microscope slides with Vectashield® Mounting Media 
containing DAPI (Vector Laboratories Inc.). The staining was visualized using Zeiss Axio 
Imager M2 fluorescence microscope. 
4.7 Cell growth and migration assays 
For cell growth analysis, cells were cultured in 24-well plate in corresponding densities: PC-3 
20,000 cells per well, and MCF-7 50,000 cells per well. One day later the cells were 
transfected with UNC13B or pSG5 control as described above. The growth area of the cells 
was measured 24 hours (day 0), 72 h (day 2) or 96 h (day 3), and 144 h (day 5) after 
transfection by imaging the cells with Olympus IX71 inverted light microscope (Olympus) 
and by using Surveyor software (Objective imaging). Images were analyzed and cell surface 
areas were determined by using ImageJ software (version 1.42q, National Institutes of 
Health). For MCF-7 cells, the transfection medium was replaced with normal growth medium 
after 6 h incubation and also the medium was changed every day before imaging the cells 
because the wells contained plenty of dead cells. All experiments were performed in six 
replicates and repeated at least twice. 
 
Together with imaging, the cell growth was studied using AlamarBlue
®
 cell viability reagent 
(Invitrogen). The cells were cultured and transfected as described above, and treated with 
AlamarBlue on days 0, 2 or 3 and 5. 50 µl of the reagent was added to the cells and 100 µl 
samples were collected after 90 min and 180 min incubations. Absorbances of the samples 
were measured spectrophotometrically at 570 nm using the 2104 EnVision
®
 Multilabel 
Reader (PerkinElmer). In this assay, increase or decrease in the metabolic activity of the cell 
culture is measured by assaying the relative absorbances of the samples. 
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Cell migration experiment was performed with PC-3 cells using standard wound healing 
assay. PC-3 cells were seeded in 24-well plate (50 000 cells per well) and 24 hours later they 
were transfected with UNC13B or pSG5 control. The cells were cultured until confluent and a 
scratch was made with a sterile pipet tip to the bottom of the wells. The scratches were 
imaged right after they were made (day 0) with Olympus IX71 inverted light microscope 
(Olympus) and Surveyor software (Objective imaging), and again 18 hours later (day 1). The 
area of the scratches was analyzed using ImageJ software (version 1.42q, National Institutes 
of Health). Experiment was performed in six replicates. 
4.8 Immunohistochemistry 
Immunostaining was performed using polyclonal rabbit antibody against UNC13B (Sigma-
Aldrich). The correct conditions for UNC13B IHC staining were first optimized using two 
antibody dilutions (1:2500 and 1:5000) and two different buffers for antigen retrieval (natrium 
citrate pH 6 and Tris-EDTA pH 9). According to the optimization, antibody dilution 1:5000 
and Tris-EDTA pH 9 for antigen retrieval were chosen for the experiment. 
 
The TMA sections of 4 µm were first deparaffinized in hexane and dehydrated in absolute 
alcohol, followed by antigen retrieval in Tris-EDTA buffer pH 9 in autoclave at 121ºC for 30 
minutes. Sections were cooled in the same buffer for 30 minutes. The antibody was diluted 
1:5000 in Normal Antibody Diluent (Immunologic) and incubated +4ºC overnight. After 
incubation the slides were washed three times 10 minutes with 1x Tris-buffered saline (TBS). 
Sections were incubated with a horseradish peroxidase-conjugated secondary antibody against 
mouse, rabbit, and rat IgGs (Poly-HRP-GAM/R/R IgG) (PowerVision+™, ImmunoVision 
Technologies) for 1 hour, and bound antibody was visualized by using diaminobenzidine 
(DAB) chromogen (UltraVision Detection System: anti-Rabbit, HRP/DAB, Thermo 
Scientific) as a HRP substrate. Sections were counterstained with Harris haematoxylin (1:4 
dilution, 4 min incubation). Staining without primary antibody was used as a negative control. 
Staining intensities were classified as negative (0), weak (1), moderate (2) and strong (3).  
 
Previously done triple staining (AMACR/p63/keratin) was used to identify adenocarcinoma 
from the TMA samples. Briefly, the triple staining was performed using a cocktail of 3 
antibodies, including antibodies against α-methylacyl-CoA racemase (AMACR), high 
molecular weight cytokeratin 34βE12, and prostate basal cell marker p63. The presence of 
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cancer was designated as blue cytoplasmic granular staining (AMACR) of the glandular 
epithelial cells in the absence of basal cells. The basal cells of benign acini had dark brown 
nuclear (p63) and cytoplasmic (34βE12) stainings. 
4.9 Statistical analyses 
Unpaired t-test or Mann-Whitney U-test was used to determine statistical difference between 
control and UNC13B transfected samples in functional assays. Kaplan-Meier analysis was 
used to test the progression free survival of prostatectomy treated patients. 
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5. RESULTS 
5.1 The expression of UNC13B in cancer cell lines 
The expression of endogenous UNC13B mRNA was determined with RT-qPCR from 
different prostate cancer cell lines (Figure 5). VCaP and DuCaP have the highest expression 
levels and 22RV1 and PC-3 have the lowest. PC-3 and LNCaP cell lines were chosen for 
overexpression experiments as they are commonly used models and thought to represent 
different stages of prostate cancer. Also, their endogenous UNC13B expression is rather low. 
 
 
Figure 5. The expression of UNC13B in different prostate cancer cell lines. There is a 
difference between the expression levels of UNC13B in prostate cancer cell lines: VCaP and 
DuCaP have the highest levels while 22RV1 and PC-3 show lowest levels of expression. 
 
 
The relative overexpression of UNC13B was determined with RT-qPCR from non-
transfected, pSG5 transfected (control), and UNC13B transfected MCF-7, PC-3, and LNCaP 
cells (Figure 6). As expected, the expression levels of UNC13B in non-transfected and pSG5 
transfected cells are negligible compared to the levels of overexpression in UNC13B 
transfected cells in all cell lines. Also, the levels of UNC13B overexpression show variability 
in studied cell lines. UNC13B expression in LNCaP is about two fold compared to MCF-7, 
and about four to five fold compared to PC-3. 
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Figure 6. The relative expression levels of UNC13B in MCF-7, PC-3, and LNCaP cell 
lines. Expression levels were determined from non-transfected (neg), pSG5 transfected 
(control), and UNC13B transfected cell lines with RT-qPCR. The difference in UNC13B 
overexpression is obvious between three studied cell lines LNCaP gaining the highest level of 
overexpression and PC-3 the lowest. Error bars indicate standard error of the mean. 
 
 
The UNC13B protein levels were determined by Western blotting from non-transfected, 
pSG5 transfected (control), and UNC13B transfected MCF-7, PC-3, and LNCaP cells (Figure 
7). Endogenous UNC13B protein level is lowest in PC-3 cells. The difference at the UNC13B 
protein levels between control and UNC13B overexpressing samples and also between 
different cell lines is somewhat contrary with the results obtained from RT-qPCR. Difference 
in UNC13B protein levels between control and UNC13B transfected cells can be seen in all 
three cell lines. However, the difference is the greatest in MCF-7 samples where UNC13B 
overexpression yields a massive increase in UNC13B protein amount whereas according to 
RT-qPCR results, the overexpression status is the greatest in LNCaP cells. Overexpression 
status in PC-3 cells is low. 
 
  MCF-7   PC-3 LNCaP 
       pSG5     UNC13B       pSG5     UNC13B         pSG5     UNC13B 
UNC13B 
 
VCP 
 
Figure 7. The quantity of UNC13B protein in control (pSG5) and UNC13B transfected 
MCF-7, PC-3, and LNCaP cell lines. There are visible differences in protein quantities 
between control and UNC13B transfected cells in all cell lines. MCF-7 gained the highest 
protein level under UNC13B overexpression. VCP was used as a loading control. 
31 
 
Fluorescence immunocytochemistry was applied to analyze UNC13B expression at the 
protein level and UNC13B localization in cancer cells. Also transfection efficiency was 
evaluated. According to visual observation the transfection efficiency was rather high in 
MCF-7 and LNCaP cells but in PC-3 cells the efficiency was significantly lower. Only few 
PC-3 cells were overexpressing UNC13B at the protein level. There was also variability in the 
UNC13B localization when overexpressed in different cell lines. In MCF-7 and LNCaP cells, 
UNC13B was localized mainly to the cell cytoplasm with some nuclear localization whereas 
in PC-3 cells the protein was localized quite evenly between the nucleus and cytoplasm. As 
expected, control cells (i.e. cells transfected with an empty expression vector) did not 
overexpress UNC13B. Representative fluorescence microscope images of transfected MCF-7, 
PC-3, and LNCaP cells are shown in Appendix 1. 
 
5.2 Cell growth and migration analyses 
The functional role of UNC13B was studied by overexpressing UNC13B in MCF-7 and PC-3 
cells, and assaying the cell growth and migration ability. The effect of UNC13B 
overexpression on growth of the cells was assessed using growth curves. The representative 
figures shown below are plotted cell area measurements gained from the microscope pictures. 
Results from alamarBlue proliferation assays are not shown because they showed great 
variability between repeated experiments and compared to results from imaging. 
5.2.1 MCF-7 cell growth 
MCF-7 cells were transfected with pSG5 or UNC13B on day -1 and imaged on days 0, 2, and 
5. Measurements gained from the microscope pictures are normalized against day 0 and 
plotted in Figure 8.  According to analyze, overexpression of UNC13B caused statistically 
significant (p<0.005) decrease in the growth of the cells. However, the inhibition of cell 
growth could be visually seen as cell death (detached from the bottom of the plates) and not 
as decelerated cell growth. 
5.2.2 PC-3 cell growth 
PC-3 cells were transfected with UNC13B on day -1 and imaged on days 0, 2 and 5. 
Measurements gained from the microscope pictures are normalized against day 1 and plotted 
in Figure 9. Overexpression of UNC13B caused slight increase with statistical significant 
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difference (p<0,05) in the growth of the cells on day 2 when comparing control and UNC13B 
cells. On day 5, the difference is not statistically significant due to the high standard deviation 
of the mean.  
 
 
Figure 8. The effect of UNC13B overexpression on MCF-7 cell growth. The cells were 
transfected with pSG5 or UNC13B on day -1 and growth area was measured on days 0, 2, and 
5. UNC13B overexpression causes decrease in the growth of the cells which results from the 
death of the cells. This figure is a representative example with error bars indicating +/- SD of 
six replicates. Measurements are normalized against day 1. **p<0.005 
 
 
 
Figure 9. The effect of UNC13B overexpression on PC-3 cell growth. The cells were 
transfected with pSG5 or UNC13B on day -1 and imaged on days 0, 2, and 5. UNC13B 
overexpression caused statistical significant reduction of the growth on day 2 but the high 
standard deviation of mean on day 5 measurements disrupts the trend. This figure is a 
representative example with error bars indicating +/- SD of six replicates. *p<0.05 
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5.2.3 PC-3 cell migration 
The effect of UNC13B overexpression to PC-3 migration ability was determined by wound 
healing assay. There is no difference in the migration ability of UNC13B transfected cells 
compared to control cells (Figure 10). 
 
Figure 10. The effect of UNC13B overexpression on PC-3 cell migration. The cells were 
transfected on day -1, scratched on day 0, and imaged on days 0 and 1. Error bars indicate +/- 
SD of six replicates. 
 
5.3 Results from clinical tumor sample specimens 
5.3.1 RT-qPCR results 
The relative expression of UNC13B in benign prostatic hyperplasia (BPH), untreated primary 
prostate cancer (PCa) and hormone refractory prostate cancer (HRPC) samples was 
determined by RT-qPCR (Figure 11). 
 
There are no statistically significant differences in the expression levels between BPH and 
PCa samples (p=0.15) or between PCa and HRPC samples (p=0.19). However, there is a trend 
seen from the graph that the mean expression of UNC13B increases together with the disease 
progression. There are also more high expression cases in the HRPC population compared to 
BPH and PCa samples. These results indicate that UNC13B might have some role in the 
phenotype of more advanced disease. 
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Figure 11. The relative expression of UNC13B in clinical prostate cancer specimens. 
Expression levels were determined by RT-qPCR and normalized against TBP expression 
levels. BPH (n=4), benign prostatic hyperplasia; PCa (n=27), untreated primary prostate 
cancer; HRPC (n=15), hormone-refractory prostate cancer. 
 
5.3.2 Immunohistochemistry results 
UNC13B expression was determined also at the protein level from 243 clinical prostatectomy 
and 115 hormone refractory prostate cancer tissue samples. IHC staining was scored from 0 to 
3 according to staining intensities (Figure 12). UNC13B was expressed in glandular epithelia 
of prostate tissue and no stromal expression was detected. UNC13B protein was localized 
mainly in the cytoplasm. Both cancer tissue and PINs expressed UNC13B (verified from 
AMACR-p63-keratin triple stained tissue specimens). UNC13B was expressed in 236 (96%) 
prostatectomy samples and in 107 (96%) HRPC samples. The expression was either moderate 
or high in most of the tissue specimens (>80%) and the distribution of staining intensities was 
similar in PCa and HRPC samples (Figure 13). These results indicate that UNC13B 
expression is rather high in cancerous cells but it’s not necessarily involved in cancer 
progression. 
 
Kaplan-Meier survival analysis was made to assess the correlation between prostatectomy 
treated patients´ progression free survival and UNC13B expression from IHC stained samples 
(Figure 14). According to analysis, UNC13B expression had no statistically significant effect 
on progression free survival (P = 0.7466). 
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Figure 12. Different immunohistochemical staining intensities for UNC13B expression in 
prostate tissue specimens. A No staining (score 0) B Weak staining (score 1) C Moderate 
staining (score 2) D Strong staining (score 3). UNC13B is localized mainly in the cytoplasm 
of glandular epithelial cells of prostate tissue. 
 
 
 
 
 
Figure 13. The distribution of UNC13B staining intensities in PCa and HRPC tissue 
specimens. PCa; untreated primary prostate cancer from prostatectomy specimen, HR; 
hormone-refractory prostate cancer specimens. Staining intensities are from no staining (0) to 
strong staining (3). 
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Figure 14. Progression free survival of prostatectomy-treated patients according to 
UNC13B. UNC13B expression had no statistically significant effect on progression free 
survival (P = 0.7466). Numeric values represent IHC staining intensities from low (1) to 
strong (3) staining. 
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6. DISCUSSION 
 
The purpose of this study was to evaluate whether UNC13B is a potential target gene of 
recently found recurrent amplification in chromosomal region 9p13.3 in prostate cancer. The 
9p13.3 region harbors multiple genes but none of them have known tumorigenic functions. 
However, mRNA expression level of some of these genes correlate with the copy number 
status, thus making them potential target genes of that amplification (Leinonen 2007, Taylor 
et al 2010). This study included in vitro functional experiments to see the impact of UNC13B 
overexpression to cancer cell proliferation and migration. The expression of UNC13B was 
also studied from clinical samples of benign prostatic hyperplasia, prostatectomy specimens 
and hormone refractory prostate cancer specimens at the level of mRNA and protein. 
 
There are no previously published studies describing UNC13B (also known as hmunc13, 
munc13-2) as a putative target gene of 9p13.3 amplicon in any cancer. UNC13B belongs to a 
small Munc13 family that comprises of C1 domain-containing proteins within the PKC 
(protein kinase C) superfamily, also containing C2 and munc13 homology domains (MHD1 
and MHD2) (Goldenberg and Silverman 2009). Munc13-1 through -4, have been previously 
studied and their roles have been identified in neurotransmitter and insulin secretion 
(Kabachinski et al 2014, Sheu et al 2003). In fact, Munc13 has been shown to be an essential 
protein for priming synaptic vesicles (Shin et al 2010). UNC13B is a cytosolic diacylglycerol 
(DAG) binding protein and it functions in Ca
2+
-triggered vesicle exocytosis. Recently, 
hmunc13 was described as an effector of the small GTPase, rab34, which belongs to Rab 
family of proteins (Speight and Silverman 2005). Rab family members are involved in 
intracellular vesicle trafficking in addition to other important cellular processes such as signal 
transduction, differentiation, proliferation, nuclear assembly, and cytoskeleton formation. 
Recent studies have shown multiple links between Rab GTPase dysfunction and associated 
regulatory proteins in human diseases, including cancer (Cheng et al 2005). 
6.1 The overexpression of UNC13B in cancer cell lines 
The UNC13B overexpression was studied by transfecting cells with an expression plasmid 
carrying the UNC13B gene and determining both mRNA and protein levels of UNC13B in 
PC-3, MCF-7 and LNCaP cell lines. The overexpression was verified at the mRNA level by 
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RT-qPCR. The results show that studied cell lines exhibited different UNC13B mRNA 
overexpression levels. LNCaP gained the highest UNC13B expression and PC-3 the lowest 
expression. Variety in expression levels could be due to differences in transfection efficiency 
which may vary greatly between cell lines and depends on the transfection method. 
 
An interesting finding was how the levels of UNC13B mRNA in MCF-7 and LNCaP cell 
lines were not correlated well with the protein levels. LNCaP showed the highest relative 
expression of UNC13B with overexpression at the mRNA level but when comparing the 
protein levels, MCF-7 cells exhibited extremely high amounts of protein. In addition, the 
difference in the quantity of protein between control transfected and UNC13B transfected 
LNCaP cells was expected be greater according to RT-qPCR results. However, the relative 
mRNA expression levels are not necessarily directly proportional to the expression level of 
the protein they code. Even relatively small changes in mRNA expression can produce large 
changes in the total amount of the corresponding protein present in the cell. The number of 
protein produced is highly dependent on translation-initiation features of the mRNA sequence 
and also translation efficiency of the cell. 
 
Reasons why MCF-7 cells gained such a high UNC13B protein amount under overexpression 
still remains a question. This might indicate differences between different cell lines in protein 
degradation, stability or translation efficiency. MCF-7 cells might translate UNC13B mRNA 
more efficiently than PC-3 and LNCaP cells yielding higher amounts of protein. Also MCF-7 
cells might have some defects in the protein degradation system so they can´t handle such a 
large amount of protein produced in a short time. For example, MCF-7 cells might lack 
certain activity and/or protein that is needed to degrade UNC13B. The possible disability to 
handle large protein amount could also explain why UNC13B transfected MCF-7 cells died so 
easily after transfection. The abnormally high protein amount might have been detrimental for 
the cells. 
 
PC-3 cells gained the lowest UNC13B mRNA and protein concentrations after transfection of 
the cell lines analyzed. According to immunocytochemistry results only few PC-3 cells 
transfected with UNC13B actually overexpressed it. These results might arise from low 
transfection efficiency which is a known weakness of transient transfection method. 
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It might also be possible that UNC13B is under a strong post-transcriptional regulation in PC-
3 cells thus leading to reduced amounts of UNC13B mRNA and protein. Possible post-
transcriptional regulatory mechanisms include mRNA splicing, export, stability and 
translation. RNA-binding proteins are responsible for much of this regulation but other 
mechanisms such as non-coding RNAs are similarly involved. These regulators recognize 
sequence motifs in target mRNAs and tag them for recognition by macromolecular complexes 
involved in RNA metabolism. Cancer cells might harbor aberrant regulatory mechanisms in 
order to achieve growth or motility advantage over normal cells (Audic and Hartley 2004). 
More studies are needed to assure whether the results reflect transfection efficiency or the 
activity of cell´s regulatory pathways. 
6.2 The effects of UNC13B expression on cancer cell growth and 
migration 
In order to study the function of UNC13B in cancer cells, PC-3 and MCF-7 cells were 
transiently transfected with UNC13B cDNA. PC-3 and MCF-7 cell lines were chosen for this 
study because they have a normal 9p13.3 copy number status and endogenous UNC13B 
expression is low in both cell lines. Thus the overexpression analysis mimics the potential 
situation that the 9p13.3 amplification would increase the expression levels of UNC13B. The 
effect of UNC13B overexpression on cell growth was determined by cell area measurements 
in a designated time interval. 
 
The effect of UNC13B overexpression on MCF-7 cell growth was difficult to determine due 
to the cells transfected with UNC13B, but not with pSG5, died very easily. MCF-7 cells might 
have suffered from the transfection mechanism of choice, although this is probably not the 
case because control cells grew rather normally. High protein levels were most likely the 
cause of MCF-7 cell death upon transfection, as discussed above. Similar effect wasn’t 
detected neither in PC-3 nor LNCaP cell lines. 
 
UNC13B overexpression had little effect on PC-3 cell growth. There was a small increase in 
the cell growth of UNC13B transfected PC-3 cells on growth measurement day 2 (3 days after 
transfection) compared to control transfected cells, however the trend was disrupted on day 5 
due to the high standard deviation of mean. These results might reflect either low transfection 
efficiency or some features of the post-transcriptional regulation in PC-3 cells, as discussed 
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above. It is also possible that the function of UNC13B in prostate cancer cells has no direct 
effect on mechanisms regulating cell proliferation. More studies are needed to resolve 
UNC13B function in cancer cells. 
 
Cell migration was studied with standard wound healing assay with PC-3 cells which are 
highly invasive cells. MCF-7 and LNCaP cells weren’t included in the migration assay 
because of their significantly lower migration ability. PC-3 cells were transfected to 
overexpress UNC13B and the wound healing was followed for 24 hours. There was no 
difference in the migration ability of UNC13B transfected cells and control transfected cells. 
This might again be due to low transfection efficiency. However, the result might also 
indicate that UNC13B does not have a role in cell migration, or that the function is not so 
straightforward that it would be apparent in the rather simple wound healing assay. 
 
Overexpression provides a useful tool to study gene function in cell culture. It would be 
interesting to see whether stable transfection of UNC13B to prostate cancer cells would 
produce different results for cell proliferation and migration assays. For stable transfection, 
introduced genetic material is integrated into the host genome and sustains transgene 
expression even after host cells replicate. In contrast, transiently transfected genes are only 
expressed for a limited period of time without integration into the genome. Furthermore, 
transiently transfected genetic material can be lost during cell division or by environmental 
factors. However, transient transfection is advantageous for fast and simple analysis of genes 
compared to laborious stable transfection which is why it was chosen for this pilot study. 
6.3 UNC13B expression in clinical prostate tissue specimens 
The expression of UNC13B was determined from clinical benign prostatic hyperplasia (BPH), 
prostate cancer (PCa) and hormone-refractory prostate cancer (HRPC) tissue samples which 
represent the transcriptome (total RNA) of a given clinical sample. The transcriptome reflects 
the genes that are being expressed at a given time excluding mRNAs which are degraded due 
to transcriptional attenuation. The relative expression of UNC13B was studied using RT-
qPCR which is a highly sensitive method to detect even small changes in mRNA expression. 
 
Results from this analysis indicate that increased expression of UNC13B may be associated 
with aggressive behavior of prostate cancer. However, the results are not statistically 
41 
 
significant. Compared to BPH and PCa, the HRPC samples showed the highest mean 
expression and also few cases of particularly high UNC13B expression which might indicate 
that UNC13B has a role in more advanced disease. There is also a wide distribution of 
UNC13B expression levels in HRPC specimens which is in parallel with the heterogeneous 
nature of prostate cancer. According to few previous large scale gene expression profile 
studies of clinical prostate cancer samples, UNC13B was found to be upregulated in 
metastatic samples compared to benign or primary prostate cancer samples (Chandran et al 
2007, Varambally et al 2005, Yu et al 2004). These results also indicate that the expression of 
UNC13B might be associated with more advanced disease, and this knowledge could possibly 
be utilized when developing a model with other parameters to predict the aggressiveness of 
the disease. Unfortunately, our study material did not include metastatic prostate cancer 
samples. More studies are needed to assess the potential use of UNC13B as a prognostic 
biomarker. 
 
Immunohistochemistry was applied to analyze the expression profile of UNC13B at the 
protein level from formalin-fixed paraffin-embedded clinical prostatectomy (n=243) and 
HRPC (n=115) tissue samples. UNC13B expression was evaluated according to staining 
intensities; no staining (0) reflecting no to negligible UNC13B expression, to strong staining 
(3) reflecting high UNC13B expression. UNC13B was located mainly in the cytoplasm of 
glandular epithelial cells and no stromal cell expression was detected. This observation seems 
valid since according to previous UNC13B studies, UNC13B has a role in vesicle transport. 
Glandular epithelial cells are specialized cells for secretion, so they obtain active vesicle 
transport system. Hence it seems logical that they gain higher UNC13B expression. 
 
The UNC13B expression was compared between prostatectomy and HRPC samples in order 
to see if the expression is different in local versus more advanced disease. According to the 
results, the distribution of staining intensities was similar in prostatectomy and HRPC 
samples indicating that UNC13B expression is not associated with cancer progression. 
However, this result does not exclude it´s potential role in the early events of tumorigenesis. It 
would be interesting to assess the UNC13B expression in normal prostate epithelial cells 
using IHC in order to see whether the expression status changes between benign and 
malignant conditions. 
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Kaplan-Meier survival analysis was performed to determine whether UNC13B expression is 
associated with progression free survival of prostatectomy treated patients. Analysis showed 
no association between progression free survival and different UNC13B expression levels. 
This indicates that UNC13B expression does not have prognostic value when examining 
prostatectomy treated patients. 
 
Immunohistochemistry is a valid technique used to detect protein localization and gene 
expression at the protein level in formalin-fixed tissue samples. The technique is based on 
specific antibody-antigen interactions and it is widely used in diagnostic and basic research to 
detect and localize protein biomarkers. Large cohorts can be screened relatively easy when 
IHC staining is combined with tissue microarray sample material. However, this technique 
requires proper optimization of several steps along the protocol. Antibody selection together 
with optimization of dilution and incubation conditions is essential, as well as choice of 
antigen retrieval method. Monoclonal antibodies are more specific than polyclonal antibodies, 
which in turn, have higher affinity and broader reactivity. Polyclonal antibodies are also prone 
to cross-reactivity as they are a mixed pool of immunoglobulins and recognize multiple 
epitopes on the same antigen. Depending on the antigen used, they can also detect different 
isoforms of proteins. The antibody used in this study was polyclonal raising a question 
whether similar results would be obtained by another UNC13B antibody. 
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7. CONCLUSIONS 
 
The aim of this thesis was to study whether UNC13B is a potential target gene of novel 
recurrent 9p13.3 amplification in prostate cancer. This study included in vitro functional 
studies to test the effect of UNC13B overexpression to prostate cancer and breast cancer cell 
proliferation. In addition, the effect of overexpression to prostate cancer cell´s migration 
ability was analyzed. 
 
The results suggest that UNC13B overexpression might slightly increase the growth of PC-3 
cells. However, the repeated experiments showed variability, decreasing the reliability of the 
results. The overexpression of UNC13B didn´t have an effect on cell´s migration ability. The 
overexpression status in PC-3 cells proved to be low. In the case of MCF-7 cells, the effect on 
proliferation was difficult to assess since the overexpression of UNC13B yielded large 
amounts of protein that the cells couldn´t tolerate. In the future, the overexpression 
experiments should be optimized for both cell lines to increase the reliability of the results. In 
addition, it would be interesting to study the post-transcriptional regulatory mechanisms of 
UNC13B which seem to differ between cell lines based on distinct overexpression status. 
 
The second aim of this thesis was to determine the expression of UNC13B in clinical prostate 
tumor specimens. The results indicate that higher UNC13B expression levels might be 
associated with more advanced disease and/or disease progression. This suggests that 
UNC13B expression profile could potentially be combined with other parameters to predict 
the aggressiveness of the disease. In the future, more studies are needed to assess the potential 
role of UNC13B in the field of prostate cancer prognostics and diagnostics. 
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9. APPENDICES 
 
 
Appendix 1. Representative fluorescence microscope images of UNC13B transfected 
MCF-7, PC-3, and LNCaP cells. The top row represents MCF-7 cells, the middle row PC-3 
cells, and the bottom row LNCaP cells. The leftmost panel shows anti-UNC13B 
immunostaining in red, the middle panel nuclear DAPI staining and the rightmost panel 
shows merged images. 
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